Onkologie 2020: 14(Suppl.E): 135-138 | DOI: 10.36290/xon.2020.073

Alectinib in the treatment of advanced ALK + NSCLC

Bohdan Kadlec
Klinika nemocí plicních a tuberkulózy LF MU a FN Brno

Alectinib - Alecenza® is a highly selective inhibitor of ALK tyrosine kinase, which has shown efficacy against mutated forms of ALK tumors, including mutations resistant to crizotinib. Its advantage is that it crosses the blood-brain barrier and is effective in the brain. It is approved as a first line monotherapy for patients with advanced ALK + NSCLC and as a treatment for patients with advanced ALK+ NSCLC progressing after previous treatment with crizotinib. The case study documents high efficacy in the treatment of patients with metastatic ALK + lung adenocarcinoma, including regression of brain metastases, without the need of cranial irradiation.

Keywords: non-small-cell lung cancer, ALK+, alectinib.

Published: September 25, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kadlec B. Alectinib in the treatment of advanced ALK + NSCLC. Onkologie. 2020;14(Suppl.E / Onkologické kazuistiky 4):135-138. doi: 10.36290/xon.2020.073.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Skřičková J, Kadlec B, Venclíček O. Nemalobuněčný karcinom plic. Vnitřní lékařství 2017; 63: 11. Go to original source...
    2. Skřičková J, Babičková L, Tomísková M, Kadlec B. Biologická léčba nemalobuněčného karcinomu plic. Interní med. 2011; (13): 7-8.
    3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; (448): 561-566. Go to original source... Go to PubMed...
    4. Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res, 2013; (19): 4273-4281. Go to original source... Go to PubMed...
    5. Shaw AT, Trap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; (27): 4247-4253. Go to original source... Go to PubMed...
    6. Choi YL, Soda M, Yamashita Y, et al. ALK Lung Cancer Study Group: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; (363): 1734-1739. Go to original source... Go to PubMed...
    7. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; (13): 1011-1019. Go to original source... Go to PubMed...
    8. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistence to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012; (18): 1472-1482. Go to original source... Go to PubMed...
    9. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011; 71: 6051-6060. Go to original source... Go to PubMed...
    10. Zhang I, Zaorsky NG, Palmer JD, et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 2015; 16: e510-e521. Go to original source... Go to PubMed...
    11. Mok T, et al. ASCEND-2: a single-arm, open-label, multicenter Phase 2 study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Annual Meeting, J Clin Oncol. 2015; 33, suppl: 8059-8059. Go to original source...
    12. Peters S, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med, 2017; 377: 829-838. Go to original source... Go to PubMed...
    13. Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 2017; 18: 1590-1599. Go to original source... Go to PubMed...
    14. Kim DW, Gadgeel S, Gettinger S, et al. Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). J Clin Oncol 2018; 36(Suppl. 15): 9009. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.